Home > Publications database > Radiosynthesis and In Vitro Evaluation of [11C]tozadenant as Adenosine A2A Receptor Radioligand > print

001     1026004
005     20250204113851.0
024 7 _ |a 10.3390/molecules29051089
|2 doi
024 7 _ |a 10.34734/FZJ-2024-03260
|2 datacite_doi
024 7 _ |a 38474602
|2 pmid
024 7 _ |a WOS:001183457000001
|2 WOS
037 _ _ |a FZJ-2024-03260
082 _ _ |a 540
100 1 _ |a Humpert, Swen
|0 P:(DE-Juel1)132740
|b 0
|u fzj
245 _ _ |a Radiosynthesis and In Vitro Evaluation of [11C]tozadenant as Adenosine A2A Receptor Radioligand
260 _ _ |a Basel
|c 2024
|b MDPI
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1714655115_25204
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Tozadenant (4-hydroxy-N-(4-methoxy-7-morpholinobenzo[d]thiazol-2-yl)-4-methylpiperidine-1-carboxamide) is a highly selective adenosine A2A receptor (A2AR) antagonist and a promisinglead structure for the development of A2AR-selective positron emission tomography (PET) probes.Although several 18F-labelled tozadenant derivatives showed favorable in vitro properties, recentin vivo PET studies observed poor brain penetration and lower specific binding than anticipated fromthe in vitro data. While these findings might be attributable to the structural modification associatedwith 18F-labelling, they could also reflect inherent properties of the parent compound. However,PET studies with radioisotopologues of tozadenant to evaluate its cerebral pharmacokinetics andbrain distribution are still lacking. In the present work, we applied N-Boc-O-desmethyltozadenantas a suitable precursor for the preparation of [O-methyl-11C]tozadenant ([11C]tozadenant) by Omethylationwith [11C]methyl iodide followed by acidic deprotection. This approach afforded[11C]tozadenant in radiochemical yields of 18 ± 2%, with molar activities of 50–60 GBq/μmol(1300–1600 mCi/μmol) and radiochemical purities of 95 ± 3%. In addition, in vitro autoradiographyin pig and rat brain slices demonstrated the expected striatal accumulation pattern and confirmedthe A2AR specificity of the radioligand, making it a promising tool for in vivo PET studies on thecerebral pharmacokinetics and brain distribution of tozadenant.
536 _ _ |a 5253 - Neuroimaging (POF4-525)
|0 G:(DE-HGF)POF4-5253
|c POF4-525
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de
700 1 _ |a Schneider, Daniela
|0 P:(DE-Juel1)156407
|b 1
700 1 _ |a Lang, Markus
|0 P:(DE-Juel1)131831
|b 2
|u fzj
700 1 _ |a Schulze, Annette
|0 P:(DE-Juel1)131847
|b 3
|u fzj
700 1 _ |a Neumaier, Felix
|0 P:(DE-Juel1)175142
|b 4
700 1 _ |a Holschbach, Marcus
|0 P:(DE-Juel1)131824
|b 5
700 1 _ |a Bier, Dirk
|0 P:(DE-Juel1)131810
|b 6
700 1 _ |a Neumaier, Bernd
|0 P:(DE-Juel1)166419
|b 7
|e Corresponding author
773 _ _ |a 10.3390/molecules29051089
|g Vol. 29, no. 5, p. 1089 -
|0 PERI:(DE-600)2008644-1
|n 5
|p 1089
|t Molecules
|v 29
|y 2024
|x 1420-3049
856 4 _ |y OpenAccess
|z StatID:(DE-HGF)0510
|u https://juser.fz-juelich.de/record/1026004/files/molecules-29-01089.pdf
856 4 _ |y OpenAccess
|x icon
|z StatID:(DE-HGF)0510
|u https://juser.fz-juelich.de/record/1026004/files/molecules-29-01089.gif?subformat=icon
856 4 _ |y OpenAccess
|x icon-1440
|z StatID:(DE-HGF)0510
|u https://juser.fz-juelich.de/record/1026004/files/molecules-29-01089.jpg?subformat=icon-1440
856 4 _ |y OpenAccess
|x icon-180
|z StatID:(DE-HGF)0510
|u https://juser.fz-juelich.de/record/1026004/files/molecules-29-01089.jpg?subformat=icon-180
856 4 _ |y OpenAccess
|x icon-640
|z StatID:(DE-HGF)0510
|u https://juser.fz-juelich.de/record/1026004/files/molecules-29-01089.jpg?subformat=icon-640
909 C O |o oai:juser.fz-juelich.de:1026004
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 0
|6 P:(DE-Juel1)132740
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 1
|6 P:(DE-Juel1)156407
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 2
|6 P:(DE-Juel1)131831
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 3
|6 P:(DE-Juel1)131847
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 4
|6 P:(DE-Juel1)175142
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 5
|6 P:(DE-Juel1)131824
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 6
|6 P:(DE-Juel1)131810
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 7
|6 P:(DE-Juel1)166419
913 1 _ |a DE-HGF
|b Key Technologies
|l Natural, Artificial and Cognitive Information Processing
|1 G:(DE-HGF)POF4-520
|0 G:(DE-HGF)POF4-525
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-500
|4 G:(DE-HGF)POF
|v Decoding Brain Organization and Dysfunction
|9 G:(DE-HGF)POF4-5253
|x 0
914 1 _ |y 2024
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-10-22
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-10-22
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2023-10-22
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2023-10-22
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b MOLECULES : 2022
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-04-10T15:26:48Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-04-10T15:26:48Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2024-04-10T15:26:48Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-16
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1150
|2 StatID
|b Current Contents - Physical, Chemical and Earth Sciences
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-16
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2024-12-16
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)INM-5-20090406
|k INM-5
|l Nuklearchemie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-Juel1)INM-5-20090406
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21